系统评价和 miRNA 对胰腺癌患者诊断准确性的荟萃分析。
Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer.
机构信息
Department of Epidemiology and Health Statistics, College of Public Health, Qingdao University, Qingdao, Shandong 266021, China.
Department of Cardiac Surgery, Qingdao Municipal Hospital, Qingdao, Shandong 266021, China.
出版信息
Dis Markers. 2018 May 15;2018:6292396. doi: 10.1155/2018/6292396. eCollection 2018.
BACKGROUND
It is reported that miRNAs are aberrantly expressed in patients with pancreatic cancer. However, the diagnostic value of miRNAs in pancreatic cancer remains controversial. The meta-analysis was to access diagnostic accuracy of miRNAs in pancreatic cancer.
METHODS
PubMed, Scopus, Web of Science, Chinese National Knowledge Infrastructure (CNKI), WANFANG Data, China Biomedical Literature Database (CBM), and VIP databases were retrieved up to June 30, 2016, to collect articles concerning the diagnosis of miRNAs in pancreatic cancer. The methodological quality of each study was assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). This meta-analysis was conducted using RevMan5.0, MetaDiSc 1.4, and Stata 12.0 software.
RESULTS
There are 40 articles including 109 studies. The pooled SEN was 0.81 (95% CI, 0.80-0.82), the pooled SPE was 0.78 (95% CI, 0.77-0.79), the pooled +LR was 3.32 (95% CI, 2.92-3.80), the pooled -LR was 0.27 (95% CI, 0.24-0.31), the pooled DOR was 14.56 (95% CI, 11.55-18.34), and pooled AUC was 0.86 (95% CI, 0.84-0.88).
DISCUSSION
This meta-analysis demonstrated that miRNA makes a significant impact in the pancreatic cancer diagnosis with a high SEN and SPE, particularly using multiple miRNAs.
背景
据报道，miRNAs 在胰腺癌患者中表达异常。然而，miRNAs 在胰腺癌中的诊断价值仍存在争议。本荟萃分析旨在评估 miRNAs 在胰腺癌中的诊断准确性。
方法
检索 PubMed、Scopus、Web of Science、中国知网（CNKI）、万方数据、中国生物医学文献数据库（CBM）和维普数据库，收集截至 2016 年 6 月 30 日关于 miRNA 诊断胰腺癌的文章。采用 Quality Assessment of Diagnostic Accuracy Studies（QUADAS-2）评价每个研究的方法学质量。本荟萃分析采用 RevMan5.0、MetaDiSc 1.4 和 Stata 12.0 软件进行。
结果
共纳入 40 篇文章，包括 109 项研究。合并后的 SEN 为 0.81（95%CI，0.80-0.82），SPE 为 0.78（95%CI，0.77-0.79），合并的+LR 为 3.32（95%CI，2.92-3.80），合并的-LR 为 0.27（95%CI，0.24-0.31），合并的 DOR 为 14.56（95%CI，11.55-18.34），合并的 AUC 为 0.86（95%CI，0.84-0.88）。
讨论
本荟萃分析表明，miRNA 对胰腺癌的诊断具有重要意义，具有较高的 SEN 和 SPE，特别是使用多个 miRNAs 时。
Zotero 插件